m Act of 1995, the company cautions investors that any
forward-looking statements or projections made by the company, including
those made in this Announcement, are subject to risks and uncertainties
that may cause actual results to differ materially from those projected.
Factors that may affect the Group's operations are described under 'Risk
Factors' in the 'Business Review' in the company's Annual Report on Form
20-F for 2006.
Note to Editors
PROMACTA(TM) is the proposed registered trademark of the
GlaxoSmithKline group of companies to be used in the United States.
To access the latest GSK news, visit http://us.gsk.com/.
US Media inquiries: Jeff McLaughlin 1 919 483 2839
Mary Anne Rhyne 1 919 483 2839
Nancy Pekarek 1 215 751 7709
US Analyst/Investor inquiries: Frank Murdolo 1 215 751 7002
Tom Curry 1 215 751 5419
(1) National Heart, Lung, and Blood Institute. Diseases and Conditions
Accessed November 12, 2007.
(2) Cines DB, Blanchette V. Idiopathic thrombocytopenic purpura. N Engl
J Med. 2002;364: 995-1008.
(3) Data on File, GlaxoSmithKline.
(4) Bussel, J., Cheng, G., Saleh, M., et al. Eltrombopag, an Oral
Platelet Growth Factor, for the Treatment of Patients with Chronic
Idiopathic Thrombocytopenic Purpura. N Engl J Med. 2007; 357(22):
(5) Cines DB, McMillan R. Management of adult idiopathic
thrombocytopenic purpura. Annu Rev Med. 2005;56:425-442.
Page: 1 2 3 4 5 Related medicine news :1
. GlaxoSmithKline Responds to JAMA Articles2
. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production3
. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results4
. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief5
. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline6
. GlaxoSmithKline Aids California Fire Relief Efforts7
. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program8
. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.9
. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds10
. GlaxoSmithKline Presents Innovative Neuroscience Pipeline11
. GlaxoSmithKline Receives FDA Complete Response Letter for Cervical Cancer Vaccine